Congratulations to NHS Market Access Accelerator alumnus Oxford Cancer Analytics (OXcan)! They, with help from MAA partners Taylor Wessing, have secured $11million in Series A funding from global investors, a strong indicator of the potential of their early lung cancer detection solution. Alongside this incredible raise they’ve also been able to expand their team, appointing Dr Heinrich Roder as Senior Vice President of Research and Development along with a raft of new Observers.
Since graduating from the MAA in 2023, OXcan have gone from strength to strength, raising millions in investment and progressing their innovation which combines advanced proteomics and tailored machine learning to transform early cancer detection using a blood test known as liquid biopsy. As an innovative product which has the potential to completely transform cancer detection and save lives, we’re tremendously proud to call OXcan an alumnus of our programme and to have supported them through their journey.
Our NHS Market Access Accelerator (MAA) is a 6-month accelerator programme, designed to provide digital health start-ups with a better understanding of how the NHS works, building a strong foundation for future growth.
To learn more about the MAA, visit our MAA page.
For more information on OXcan, visit their website.